As President Donald Trump vows to bridge the drug pricing gap between the U.S. and other developed countries with his “most ...

Pfizer CEO Albert Bourla, Ph.D., has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing ...

The president wants foreign countries to pay more for drugs made in the US to help Big Pharma firms make more money abroad.

Britain faces paying more for US drugs as part of a deal to avoid future tariffs from Donald Trump. The NHS will review drug ...

Pfizer Inc. (NYSE:PFE) is one of the best wide moat stocks to buy now. On June 9, Pfizer, along with other drug manufacturers ...

Pfizer (PFE) and other drugmakers met with the Trump administration to discuss lowering U.S. drug prices but no commitments have been made, Pfizer CEO Albert Bourla said on Monday at the Goldman Sachs ...

The decision of the General Court of the European Union in the Pfizergate case would allow the European Commission to ...

Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert Bourla, that landed in Pfizer’s cancer ...

Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. | Pfizer's CEO ...

Industry sources reveal drug companies have stopped negotiating listings on the PBS and in some cases are considering not ...

According to the order, the administration was to set "most favored nation" price targets within 30 days. The Department of ...